News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

Soon Shiong on Twitter 14 min ago Excited to be presenting at the Africa’s Vaccine Manufacturing For Health Security virtual conference at 9am PST. Link is below https://zoom.us/webinar/&register/WN_U31MVTQvQlWY51LbsEKT-w… Generating capacity and self-sufficiency for a billion people in Africa! Will lead from South Africa!

An oral vaccine being developed by one of the owners of the Los Angeles Lakers could offer protection from COVID-19 without the need for an injection, CBS Los Angeles reports. Researchers at the Chan Soon-Shiong Research Institute in El Segundo are testing whether a series of capsules might work as well as, or even better than, than existing COVID vaccines. "To have a vaccine that's room temperature that could be a pill is life-changing," Dr. Tara Seery, a trial physician, said. The oral vaccine is part of an experimental protocol being tested in healthy volunteers. But since scientists still don't know if pills alone can prevent transmission, the researchers are testing four different approaches. Some participants get a shot and some don't. Some, like Matt Henshaw, get one injection and two rounds of pills. But the delivery of the vaccine in a capsule isn't the only thing differentiating this vaccine from others. While existing vaccines help create antibodies to the spike protein on the surface of the coronavirus, ImmunityBio's T cell vaccine targets the globe in the middle — a part scientists say is less prone to mutation. "And the value of doing so is that we generate killer T cells," said ImmunityBio founder and executive chairman Dr. Patrick Soon-Shiong, who's a Lakers owner as well as a vaccine mastermind. The researchers at ImmunityBio hypothesize that they can create long-term protection against the virus by generating both killer T-cells and antibodies. Soon-Shiong believes there's reason for optimism for lasting protection, even though the Operation Warp Speed-funded vaccine candidate is still in the experimental stages with safety and efficacy yet to be proven. "We know from previous SARS-COV-1 in 2003, (that) people (who) got infected then have T-cells that have lasted for 17 years," he said. As for delivering the vaccine orally, it's not just to avoid a shot. Soon-Shiong believes the combination of the two could be the key. "By giving a jab, we hope to develop T-cells all around your body," he said. "And by giving orally, we protect the mucus membranes, the gut and hopefully the nose, the mouth, because that's how the virus comes in. It doesn't come in through your blood." As for Henshaw, now that he's finished his vaccine and boosters, he'll undergo intensive monitoring for the next 12 months and hopes his experience will encourage others to enter a trial. "The virus is mutating," he said. "So, I hope that we have solutions." The trial is open to healthy adults under the age of 55 who aren't pregnant and haven't had COVID. More information about the vaccine trial can be found on ImmunityBio's website. https://www.google.com/amp/s/www.cbsnews.com/amp/news/covid-19-vaccine-oral-testing-los-angeles/

THURSDAY, April 8, 2021 (HealthDay News) -- California researchers are testing whether an oral vaccine offers similar or better protection than current COVID-19 shots. The capsule-delivered vaccine under development at the Chan Soon-Shiong Research Institute in El Segundo is being tested in healthy volunteers, CBS News reported. Existing vaccines promote production of antibodies to the spike protein on the surface of the coronavirus that causes COVID-19, but the ImmunityBio T cell oral vaccine targets the globe in the middle of the virus, a part that is less prone to mutation, according to scientists. "And the value of doing so is that we generate killer T cells," ImmunityBio founder and Executive Chairman Patrick Soon-Shiong, M.D., told CBS News. The ImmunityBio researchers believe they may be able to create long-term protection by generating both antibodies and killer T cells. https://consumer.healthday.com/oral-covid-19-vaccine-being-tested-2651383810.html?fbclid=IwAR24Kkzpup9TeZdcDqdnV1IM8rVabnbiIqAElZh4WZJXSoS9-0X7qra9FWk

Announcing preliminary Phase 1 data, ImmunityBio (NASDAQ:IBRX) has highlighted the potential of its experimental dual antigen hAd5 S + N vaccine against COVID-19 to provide long-term protection as well as immunity against the new coronavirus variants. A single subcutaneous injection of the shot in healthy subjects has generated T cells that are reactive to the spike (NYSE:S) and nucleocapsid (NYSE:N) protein antigens delivered by the vaccine, the company said. By day 21, T cell responses against both S and N antigens reached levels have reached ten times higher than the pre-vaccination levels. The mean T cell levels in those inoculated with the vaccine were equivalent to patients recovered from the COVID-19 infection. However, the data are yet to be peer-reviewed and are published in the preprint server medRxiv. Targeting the S protein of the virus, the current generation of vaccines are less effective against coronavirus variants, noted, Patrick Soon-Shiong, CEO of ImmunityBio. “Our goal is to develop the second-generation COVID-19 vaccine which is room temperature stable, can be self-administered orally, and generates both antibody and long-term T cell immunity,” Dr. Soon-Shiong added. Phase 1b trials are ongoing to find the best combination of subcutaneous, oral, or sublingual forms of hAd5 S+N to achieve maximum protection. The T cell-based, viral vector vaccine candidate generated no serious adverse events, according to interim data from a Phase 1 study involving 12 subjects. https://seekingalpha.com/news/3680347-immunitybio-posts-early-stage-interim-data-showing-potential-of-covid-19-vaccine?utm_source=feed_news_all&utm_medium=referral

Ist schon etwas älter, trotzdem interessant, wer da so eingestellt wurde: CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately. https://www.businesswire.com/news/home/20210224005400/en/ImmunityBio-Appoints-John-Brennan-and-Wesley-Clark-to-Board-of-Directors

ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2 https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-single-prime-had5-covid-19-vaccination?field_nir_news_date_value[min]=

2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) June 4-8, 2021 (Virtual)

Dr. Maxwell is a medical educator, surgeon, and health technology entrepreneur and innovator. She has guided a wide variety of startup companies through clinical development capitalization and commercialization as Founder and Executive Director of the Biomedical Zone.

ImmunityBio, Inc. @ImmunityBio · 8 Std. Today, we have announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company's board of directors. We have also appointed CEO Richard Adcock to the board. https://t.co/gMaH78nt7f?amp=1

ImmunityBio on Twitter 12 hkurs ago: COVID-19 also isn’t the only virus affecting #SouthAfrica. SA has one of the highest HIV infection rates globally; 7.7 million people—19% of adult population. SA is in dire need of greater access to vaccines, not just for COVID-19 but for the future.

ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-12-month-overall-survival-probability-83?field_nir_news_date_value[min]=

Yahoo Finance Presents: Dr. Patrick Soon-Shiong ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong sat down with Yahoo Finance’s Anjalee Khemlani to discuss the recent growth of ImmunityBio, it’s work on a vaccine for the coronavirus, and the biotech industry. https://www.google.com/amp/s/money.yahoo.com/amphtml/yahoo-finance-presents-dr-patrick-190000914.html

In case unseen, we recently announced results from an NIH-led preclinical study that suggests our PD-L1 t-haNK cells in combination with T cell-based immunotherapy enhance rates of durable tumor control in patients with relapsed solid tumors: https://jitc.bmj.com/content/9/3/e002128

ImmunityBio announces publication of data highlighting efficacy of PD-L1 t-haNKs in combination with T cell-based immunotherapy against heterogeneous tumors  (35.53) ImmunityBio announced the publication of preclinical data in the Journal for ImmunoTherapy of Cancer highlighting efficacy of ImmunityBio's PD-L1 t-haNK natural killer cell-based therapy in combination with T cell-based immunotherapy against heterogeneous tumors. ImmunityBio's novel PD-L1 t-haNKs are derived from a human, allogeneic NK cell line (NK-92) that has been engineered to express IL-2, CD16, and a chimeric antigen receptor that recognizes PD-L1. This study supports ImmunityBio's hypothesis of combining NK cells with T cell activation in Phase 2/3 trials in metastatic pancreatic and lung cancers.